LAAE-14, a new anti-inflammatory drug, increases the survival of Candida albicans-inoculated mice.
LAAE-14, a lipidic acid-amido ether derivative, has been recently described as a new anti-inflammatory drug. We have studied the effect of treatment with this compound on the susceptibility of mice to in vivo experimental Candida albicans infection. ICR mice orally treated with LAAE-14 (25 mg kg(-1)) and experimentally intravenously infected showed a significantly increased survival as compared to control mice. In vitro, the compound did not inhibit the growth of C. albicans yeast cells or the yeast-to-hyphal transition. The in vitro production of prostaglandin E2 by peritoneal macrophages in response to the yeasts and hyphae of C. albicans was significantly decreased upon treatment with LAAE-14, in a dose-dependent manner. Thus, reduced prostaglandin production during fungal infection could be an important factor in controlling fungal colonisation and infection.
Lucas
Rut
R
Departamento de Farmacología, Universidad de Valencia, Avda V Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain.
Villamón
Eva
E
Payá
Miguel
M
Alves
Mario
M
del Olmo
Esther
E
Gozalbo
Daniel
D
Gil
M Luisa
ML
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects / Q000254:growth & development; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D002478:Cells, Cultured; D015232:Dinoprostone / Q000378:metabolism; D004195:Disease Models, Animal; D005977:Glutarates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D025301:Hyphae / Q000187:drug effects / Q000254:growth & development; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D016019:Survival Analysis
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005977:Glutarates; C488682:LAEE 14 compound; D015232:Dinoprostone